Comparing burosumab to traditional phosphate and active vitamin D supplements in treating pediatric XLH patients is crucial due to burosumab’s targeted mechanism of inhibiting FGF23, potentially offering more direct correction of the underlying phosphate wasting. Here, FGF23 is linked to X-linked hypophosphatemia.